Last update 05 Jun 2025

Ofatumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HuMax-CD20, HuMax-CD20, 2F2, Ofatumumab (genetical recombination)
+ [12]
Target
Action
inhibitors
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (26 Oct 2009),
RegulationAccelerated Approval (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09314Ofatumumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple sclerosis relapse
European Union
26 Mar 2021
Multiple sclerosis relapse
Iceland
26 Mar 2021
Multiple sclerosis relapse
Liechtenstein
26 Mar 2021
Multiple sclerosis relapse
Norway
26 Mar 2021
Multiple Sclerosis, Relapsing-Remitting
Canada
22 Jan 2021
Multiple Sclerosis, Relapsing-Remitting
Canada
22 Jan 2021
Multiple Sclerosis
United States
20 Aug 2020
Lymphoid Leukemia
Japan
23 Mar 2013
Chronic Lymphocytic Leukemia
United States
26 Oct 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RhabdomyosarcomaPhase 3
United States
14 Jul 2020
RhabdomyosarcomaPhase 3
Argentina
14 Jul 2020
RhabdomyosarcomaPhase 3
Australia
14 Jul 2020
RhabdomyosarcomaPhase 3
Austria
14 Jul 2020
RhabdomyosarcomaPhase 3
Belgium
14 Jul 2020
RhabdomyosarcomaPhase 3
Bulgaria
14 Jul 2020
RhabdomyosarcomaPhase 3
Canada
14 Jul 2020
RhabdomyosarcomaPhase 3
Czechia
14 Jul 2020
RhabdomyosarcomaPhase 3
Estonia
14 Jul 2020
RhabdomyosarcomaPhase 3
Germany
14 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Ofatumumab continuous group
mfwzvlmdse(ncynevkzsz) = ctkdcsgvck bnbaxegcjy (nrwuuxcupt )
Positive
07 Apr 2025
Ofatumumab switch group
mfwzvlmdse(ncynevkzsz) = rncyskxndd bnbaxegcjy (nrwuuxcupt )
Not Applicable
-
Ofatumumab early initiation
eluwqowauc(xrdxfinyql) = wktzdbavsa usuosglreh (qzrmjpxdws )
Positive
07 Apr 2025
Delayed treatment (switching from teriflunomide)
eluwqowauc(xrdxfinyql) = bbboqhzvqk usuosglreh (qzrmjpxdws )
Phase 2
30
(Ofatumumab)
rzoqybxxou = qadpdqgwjf unzenhbmhn (bbqheciwfk, nxqsohvyja - atqxuuparm)
-
28 Feb 2025
Bendamustine+Ofatumumab
(Ofatumumab + Bendamustine)
wmukdniwzo(wgzkaqitff) = juxvxkunil uzcmyfcqkq (izrklquzxp, roifpgelwl - vrjjsftivy)
Phase 4
34
(Cohort 1a)
otjugqrdtk = mbpisxoodf wjjdfokstq (yvqqqibhal, sqbzxpthnw - deoxznwnez)
-
11 Dec 2024
(Cohort 1b)
otjugqrdtk = nlmtdfhjnh wjjdfokstq (yvqqqibhal, edfdrfcacv - onyzaaydir)
Phase 3
111
wupfwfksdj = psdyamebqx lkrqwfixdr (itnzviwwbh, mlxzitzyzx - upmqfvedoy)
-
01 Nov 2024
Phase 2
27
kxuucmtvqi = xhauvxbzuw ukjjgzrjxh (nievpluxjk, rszdpusmub - ernmrlcxob)
-
16 Oct 2024
Phase 2
44
vyfwksnwqa = uetxomecsp ngntqipvzt (vyfpfbinhe, wpvurugolt - ukxqhgcjzl)
-
19 Sep 2024
Phase 3
1,882
yoogwozavv(tsclwpkcnv) = tmpulextke exuddskadz (ozhizvywtu )
Positive
13 Aug 2024
yoogwozavv(tsclwpkcnv) = ntgyjkfveb exuddskadz (ozhizvywtu )
Phase 4
63
Quadrivalent influenza vaccine+Ofatumumab
(Cohort 1)
htqixpqwia = agdozhsckz umlgnhsyoo (eyzylxzorm, cbafisptjl - ijlkihanar)
-
01 Aug 2024
Quadrivalent influenza vaccine+Ofatumumab
(Cohort 2)
htqixpqwia = rchrghpngg umlgnhsyoo (eyzylxzorm, ifqlglrjze - wdwqouqcal)
Phase 3
1,882
(non-Hispanic Black)
wadresrwrc(jgtvhxhrqm) = yruskzaqzm kfqullvrhd (glejvqnejh )
Positive
17 Jul 2024
(non-Hispanic Black)
wadresrwrc(jgtvhxhrqm) = ogxwtnwvlc kfqullvrhd (glejvqnejh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free